Quantitative immunocytochemical assays of topoisomerase II in lung adenocarcinoma cell lines - Correlation to topoisomerase IIα content and topoisomerase II catalytic activity

Acta Oncologica

Volumn 35, Issue 4, 1996, Pages 417-423

  Yamazaki, Kohichi ^a   Isobe, Hiroshi ^a   Hanada, Tarou ^a   Sukoh, Noriaki ^a   Ogura, Shigeaki ^a   Kawakami, Yoshikazu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING);

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LUNG ADENOCARCINOMA; PRIORITY JOURNAL;

EID: 0030036686     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609109915     Document Type: Article

References (38)

1. Berrios M, Osheroff N, Fisher PA. In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction. Proc Natl Acad Sci USA 1985; 82: 4142-6.
2. Andoh T. Biological functions of DNA topoisomerases. Jpn J Cancer Chemother 1991; 18: 1543-9 (in Japanese).
3. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351-75.
4. Drake FH, Zimmerman JP, McCabe FL, et al. Purification of topoisomerase II form amsacrine-resistant P388 leukemia cells. J Biol Chem 1987; 262: 16739-47.
5. Chung TDY, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK. Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci USA 1989; 86: 9431-5.
6. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 1989; 28: 8154-60.
7. Prosperi E, Sala E, Negri C, et al. Topoisomerase IIα and β in human tumor cell grown in vitro and in vivo. Anticancer Res 1992; 12: 2093-100.
8. Nitiss JL, Liu Y-X, Harbury P, Jannatipour M, Wasserman R, Wang JC. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res 1992; 52: 4467-72.
9. van der Zee AGJ, de Jong S, Keith WN, Hollema H, Boonstra H, de Vries EGE. Quantitative and qualitative aspects of topoisomerase I and IIα and β in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res 1994; 54: 749-55.
10. Takano H, Kohno K, Ono M, Uchida Y, Kuwano M. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 1991; 51: 3951-7.
11. Mirski SEL, Evans CD, Almquist KC, Slovak ML, Cole SPC. Altered topoisomerase IIα in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res 1993: 53: 4866-73.
12. Matsuo K, Kohno K, Takano H, Sato S, Kiue A, Kuwano M. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines. Cancer Res 1990; 50: 5819-24.
13. Lee M, Wang JC, Beran M. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J Mol Biol 1992; 223: 837-43.
14. Bugg BY, Danks MK, Beck WT, Suttle DP. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Biochemistry 1991; 88: 7654-8.
15. McPherson JP, Brown GA, Goldenberg GJ. Characterization of a DNA topoisomerase IIα gene rearrangement in adriamycin-resistant P388 leukemia: Expression of a fusion messenger RNA transcript encoding topoisomerase IIα and the retinoid acid receptor a locus. Cancer Res 1993; 53: 5885-9.
16. Hasegawa T, lsobe K, Nakashima I, Shimokata K. Higher expression of topoisomerase II in lung cancers than normal lung tissues: Different expression pattern from topoisomerase I. Biochem Biophys Res Commun 1993; 195: 409-14.
17. McKenna SL, Whittaker JA, Padua RA, Holmes JA. To-poisomerase II expression in normal haemopoietic cells and chronic lymphocytic leukemia: Drug sensitivity or resistance. Leukemia 1993; 7: 1199-203.
18. Potmesil M, Hsiang Y, Liu LF, et al. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 1988; 48: 3537-43.
19. Tandon AK, Hilsenbeck SG, Clark GM, et al. Significance of topoisomerase II in clinical breast cancer. Proc Amer Assoc Cancer Res 1991; 32: 350.
20. van de Zee AGJ, Hollema H, de Jong S, et al. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 1991; 51: 5915-20.
21. Wolverton JS, Danks MK, Granzen B, Beck WT. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors. Cancer Res 1992; 52: 4248-53.
22. Efferth T, Mattern J, Volm M. Immunohistochemical detection of P glycoprotein, glutathione S transferase and DNA to-poisomerase II in human tumors. Oncology 1992; 49: 368-75.
23. Kaufmann SH, McLaughlin SJ, Kastan MB, Liu LF, Karp JE, Burke PJ. Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res 1991; 51: 3534-43.
24. Volm M, Mattern J. Expression of topoisomerase II, catalase, metallothionein and thymidylate-synthase in human squamous cell lung carcinomas and their correlation with doxorubicin resistance and with patients' smoking habits. Carcinogenesis 1992; 13: 1947-50.
25. Volm M, Kastel M, Mattern J, Efferth T. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-π, and topoisomerase II) and their interrelationship to protooncogene products in renal cell carcinomas. Cancer 1993; 71: 3981-7.
26. Tuccari G, Rizzo A, Giuffre' G, Barresi G. Immunocytochemical detection of DNA topoisomerase type II in primary breast carcinomas: Correlation with clinico-pathological features. Virchows Archiv A Pathol Anat 1993; 423: 51-5.
27. Heck MMS, Earnshaw WC. Topoisomerase II: A specific marker for cell proliferation. J Cell Biol 1986; 103: 2569-81.
28. Isobe H, Miyamoto H, Shimizu T, et al. Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer. Cancer 1990; 65: 1391-5.
29. Deffie AM, Batra JK, Goldenberg GJ. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 1989; 49: 58-62.
30. Kasahara K, Fujiwara Y, Sugimoto Y, et al. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human cancer cell lines. J Natl Cancer Inst 1992; 84: 113-8.
31. Muller MT, Helal K, Soisson S, Spitzner JR. A rapid and quantitative microtiter assay for eukaryotic topoisomerase II. Nuc Acid Res 1989; 17: 9499.
32. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colori metric assay: Assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-42.
33. Scudiero DA, Shoemaker RH, Paull KD, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988; 48: 4827-33.
34. Negri C, Chiesa R, Cerino A, et al. Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymes. Exp Cell Res 1992; 200: 452-9.
35. Zini N, Martelli AM, Sabatelli P, et al. The 180-kDa isoform of topoisomerase II is localized in the nucleolus and belongs to the structural elements of the nucleolar remnant. Exp Cell Res 1992; 200: 460-6.
36. Heck MMS, Hittelman WN, Earnshaw WC. Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 1988; 85: 1086-90.
37. Hsiang Y-H, Wu H-Y, Liu LF. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 1988; 48: 3230-5.
38. Feldhoff PW, Mirski SEL, Cole SPC, Sullivan DM. Altered subcellular distribution of topoisomerase IIα in a drug-resistant human small cell lung cancer cell line. Cancer Res 1994; 54: 756-62.